Why It Matters

Humacyte Inc. is escalating its lobbying efforts at a critical moment for its commercial viability. Its recently approved Symvess device faces the well-documented gap between FDA authorization and Medicare coverage—a problem Congress is actively working to solve through the Patient Access to Innovative New Technologies Act of 2025.

By hiring Capitol Hill Consulting Group, Humacyte has assembled a team with exceptional strategic positioning. This represents a significant upgrade from Humacyte’s previous lobbying approach. The company has worked with multiple specialized firms since 2011, but has never before engaged a top-tier firm of CHCG’s scale and influence.

By the Numbers

Humacyte Inc. has invested approximately $1.39 million in federal lobbying since 2011. The company’s new registration with Capitol Hill Consulting Group adds four experienced lobbyists two of whom bring decades of high-level experience on the exact committees controlling device payment policy: .

  • Brian D. Sutter: 13.5 years of House experience, including Staff Director for the Ways and Means Health Subcommittee
  • Kimberlee Rae Trzeciak: 16+ years of congressional experience, including Chief Adviser for Health on the House Energy and Commerce Committee
  • Christopher Davis: Nearly 6 years of House experience as Legislative Director/Senior Policy Adviser
  • Emily Elizabeth Wilkinson Holland: Over 6 years of congressional experience in the House and Senate

The Agenda

Humacyte Inc. is lobbying to secure favorable payment policies for its approved medical devices. The company’s bioengineered blood vessel product has received FDA approval, making Medicare reimbursement a critical business priority.

Humacyte is engaging as Congress pursues bipartisan legislative efforts to address the "valley of death"—the gap between FDA approval and Medicare coverage for breakthrough medical technologies. Key bills include the Patient Access to Innovative New Technologies Act of 2025 and the Amputation Reduction and Compassion Act of 2025.

Broader Context

Congress is actively working to solve the "valley of death" problem. The House Energy and Commerce Committee recently held hearings on enabling seniors’ access to breakthrough technologies, signaling strong bipartisan momentum for reform.

Humacyte’s timing is strategic. The company’s flagship product, Symvess, recently received FDA approval for vascular trauma repair and is launching commercially in early 2025. CMS finalized a new "Transitional Coverage for Emerging Technologies" rule in 2024, creating faster Medicare pathways for FDA-designated breakthrough devices. However, the program accepts only approximately five device makers annually, intensifying competition.

Between The Lines

A bipartisan coalition including Reps. Blake Moore and Lori Trahan advanced breakthrough device coverage legislation through the Ways and Means Committee with a 38-3 vote. In the Senate, Senators Alex Padilla and Todd Young introduced companion legislation, noting seniors wait over five years for Medicare coverage after FDA authorization.

Competitive Landscape

Humacyte joins a broad industry coalition seeking favorable medical device payment policies. The Medical Device Manufacturers Association, Zimmer Biomet Holdings Inc., and SI-BONE Inc. are all lobbying on similar reimbursement issues, creating powerful momentum for payment reform measures.

The Bottom Line

Humacyte has hired Capitol Hill Consulting Group to secure favorable Medicare reimbursement for its bioengineered blood vessels as Congress pursues bipartisan legislation to eliminate the "valley of death." The company now joins a broad industry coalition pushing for payment reform at a moment of clear congressional receptivity.